Alpha Tau Medical (DRTS)

The company’s proprietary approach is designed to address one of the traditional limitations of alpha radiation: its short range. Instead of viewing that characteristic only as a constraint, Alpha Tau uses it as part of the treatment concept. Alpha DaRT involves the placement of sources that release alpha-emitting atoms within the tumor environment, creating a localized effect intended to concentrate radiation where it is needed most. This differs from many external-beam radiation approaches and from systemic radiopharmaceuticals that circulate through the body.

Alpha Tau is evaluating the platform across multiple solid tumor indications. Its clinical programs include studies in areas such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. The breadth of the pipeline reflects the company’s belief that a localized alpha-radiation approach may have relevance in tumors that are accessible for placement of the treatment device.

The company operates internationally, with activities connected to Israel, the United States, and Japan. As a development-stage medical technology and therapeutics business, Alpha Tau’s progress depends on clinical trial outcomes, regulatory review, manufacturing execution, physician adoption, and the ability to demonstrate that its technology offers meaningful advantages over existing cancer treatment options.